446 related articles for article (PubMed ID: 34407318)
1. Review of CFTR modulators 2020.
Goetz DM; Savant AP
Pediatr Pulmonol; 2021 Dec; 56(12):3595-3606. PubMed ID: 34407318
[TBL] [Abstract][Full Text] [Related]
2. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
3. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
4. Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation.
Antos NJ; Savant AP
Pediatr Pulmonol; 2022 Feb; 57(2):347-360. PubMed ID: 34033706
[TBL] [Abstract][Full Text] [Related]
5. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
[TBL] [Abstract][Full Text] [Related]
6. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
7. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
Mayer-Hamblett N; Boyle M; VanDevanter D
Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
[TBL] [Abstract][Full Text] [Related]
8. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
9. Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy.
Hisert KB; Birket SE; Clancy JP; Downey DG; Engelhardt JF; Fajac I; Gray RD; Lachowicz-Scroggins ME; Mayer-Hamblett N; Thibodeau P; Tuggle KL; Wainwright CE; De Boeck K
Lancet Respir Med; 2023 Oct; 11(10):916-931. PubMed ID: 37699420
[TBL] [Abstract][Full Text] [Related]
10. Use of CFTR modulators in special populations, part 2: Severe lung disease.
Elijah J; Fitzgerald LJ; Phan H
Pediatr Pulmonol; 2023 Dec; 58(12):3386-3392. PubMed ID: 37728222
[TBL] [Abstract][Full Text] [Related]
11. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
12. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
[TBL] [Abstract][Full Text] [Related]
13. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
14. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.
Mitchell RM; Jones AM; Barry PJ
Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080
[TBL] [Abstract][Full Text] [Related]
15. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
Bulloch MN; Hanna C; Giovane R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
[TBL] [Abstract][Full Text] [Related]
17. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
Brewington JJ; McPhail GL; Clancy JP
Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
[TBL] [Abstract][Full Text] [Related]
18. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
Sergeev V; Chou FY; Lam GY; Hamilton CM; Wilcox PG; Quon BS
Ann Am Thorac Soc; 2020 Feb; 17(2):147-154. PubMed ID: 31661636
[TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.
Egan ME
Curr Opin Pediatr; 2020 Jun; 32(3):384-388. PubMed ID: 32374578
[TBL] [Abstract][Full Text] [Related]
20. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
Lommatzsch ST; Taylor-Cousar JL
Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
